EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast

Chloe S Lalonde iD, Jeffrey M Switchenko iD, Madhusmita Behera, Mehmet A Bilen, Taofeek K Owonikoko iD, Jonathan L Kaufman, Ajay K Nooka, Colleen M Lewis, Elise Hitron, Hannah Collins, Emma C Judson, Olatunji B Alese iD und 2 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad181 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Oncologist, 2023. Verfasst von Chloe S Lalonde und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Ethnicity, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Winship Cancer Institute of Emory University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Racial and ethnic minority populations are consistently under-represented in oncology clinical trials despite comprising a disproportionate share of a cancer burden. Phase I oncology clinical trials pose a unique challenge and opportunity for minority inclusion. Here we compared the sociodemographic characteristics of patients participating in phase 1 clinical trials a National Cancer Institute ( NCI)-designated comprehensive center to all patients at the center, patients with new cancer diagnosis in metropolitan Atlanta and patients with new cancer diagnoses in the state of Georgia. From 2015 to 2020, 2325 patients (43.4% female, 56.6% male) consented to participate in a phase I trial. Grouped self-reported race distribution was 70.3% White, 26.2% Black, and 3.5% other. Of new patient registrations at Winship Cancer Institute (N = 107 497) (50% F, 50% M), grouped race distribution was 63.3% White, 32.0% Black, and 4.7% other. Patients with new cancer diagnoses in metro Atlanta from 2015 to 2016 (N = 31101) were 58.4% White, 37.2% Black, and 4.3% other. Race and sex distribution of phase I patients was significantly different than Winship patients (P < .001). Over time, percent of White patients decreased in both phase I and Winship groups (P = .009 and P < .001, respectively); percentage of females did not change in either group (P = .54 phase I, P = .063 Winship). Although phase I patients were more likely to be White, male, and privately ensured than the Winship cohort, from 2015 to 2020 the percentage of White patients in phase I trials and among all new patients treated at Winship decreased. The intent of characterizing existing disparities is to improve the representation of patients from racial and ethnic minority backgrounds in phase I clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EthnicityNeoplasmsUnited StatesHumansMaleFemaleMinority GroupsNational Cancer Institute (U.S.)Georgia

Stichwörter der Autor:innen

Clinical triaPhase 1equity

Autor:innen und Institutionen

  • Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
  • Department of Biostatistics and Bioinformatics, Rollins School of Public Health of Emory University, Atlanta, GA, USA.
  • Winship Cancer Institute of Emory University, Atlanta, GA, USA.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
  • Department of Hematology and Medical Oncology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Florida Cancer Specialists, Tampa, FL, USA.

ORCID-Profile: Chloe S Lalonde, Jeffrey M Switchenko, Taofeek K Owonikoko, Olatunji B Alese, R Donald Harvey, Jennifer W Carlisle

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Winship Cancer Institute of Emory University
  • National Institutes of Health
  • NCI

Zitieren

APA

Lalonde, C. S., Switchenko, J. M., Behera, M., Bilen, M. A., Owonikoko, T. K., Kaufman, J. L., Nooka, A. K., Lewis, C. M., Hitron, E., Collins, H., Judson, E. C., Alese, O. B., Donald Harvey, R., & Carlisle, J. W. (2023). Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast. The Oncologist. https://doi.org/10.1093/oncolo/oyad181

Vancouver

Lalonde CS, Switchenko JM, Behera M, Bilen MA, Owonikoko TK, Kaufman JL, et al. Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast. The Oncologist. 2023. doi:10.1093/oncolo/oyad181

BibTeX
@article{Lalonde2023,
  author = {Lalonde, Chloe S and Switchenko, Jeffrey M and Behera, Madhusmita and Bilen, Mehmet A and Owonikoko, Taofeek K and Kaufman, Jonathan L and Nooka, Ajay K and Lewis, Colleen M and Hitron, Elise and Collins, Hannah and Judson, Emma C and Alese, Olatunji B and Donald Harvey, R and Carlisle, Jennifer W},
  title = {Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad181}
}
Kostenlos starten →